Metformin treatment in NIDDM patients with mild renal impairment

Vincent Connolly, Colin M Kesson

Summary
Metformin is contraindicated in patients with renal failure because of the risk of lactic acidosis. This study assessed the complications of metformin treatment in patients with non-insulin-dependent diabetes mellitus with normal and raised serum creatinine. Subjects using metformin with serum creatinine above the upper reference range (120 μmol/l) were identified (n=17) from a hospital diabetes register; those with abnormal liver function, cardiac failure, peripheral vascular disease or recent severe illness were excluded. Reference plasma lactate levels were established, mean 1.742 μmol/l (SD 0.819) using age-matched non-diabetic subjects. Age-matched patients treated with metformin with normal serum creatinine levels formed the control group (n=24). Details of gastrointestinal disturbance were recorded, and plasma lactic acid and vitamin B12 levels measured.

The median total daily dose of metformin in both groups was 1700 mg. The mean plasma lactate in subjects with serum creatinine 80–120 μmol/l (2.640 mmol/l) (SD 1.434) p < 0.02) was higher than non-diabetic control levels while diabetic subjects with serum creatinine 120–160 μmol/l had a mean of 2.272 mmol/l (SD 0.763) p < 0.05. There was no significant difference between the two groups taking metformin, nor any significant difference in the reporting of gastrointestinal symptoms between the groups on metformin (11.76% vs 12.5%).

Plasma lactic acid levels are higher in diabetic subjects taking metformin compared with healthy volunteers but, within the diabetic groups, the small elevation of serum creatinine was not associated with higher plasma lactate levels.

Keywords: metformin, diabetes mellitus, lactate

Biguanides were first introduced for the treatment of non-insulin dependent diabetes mellitus (NIDDM) in 1957. An association with lactic acidosis resulted in the withdrawal of phenformin in 1976, but presentation of metformin continued. The benefits of metformin use are related to its antihyperglycaemic effect, reducing fasting blood glucose levels, without causing hypoglycaemia. Furthermore, beneficial properties are noted in terms of weight reduction, reduction of triglyceride and cholesterol levels, increased fibrinolytic activity, reduction in plasminogen activator inhibitor, without an increase in peripheral insulin levels. All of these beneficial effects confirm the efficacy of metformin, particularly in obese subjects with type 2 diabetes. However, metformin-like phenformin has been implicated in the causation of lactic acidosis and this has been associated with renal impairment, which reduces the clearance of metformin. This has led to the practice of avoiding metformin in renal impairment. A clear cut-off point has not been defined, although a serum creatinine >120 μmol/l has been suggested. We conducted a case-control study of NIDDM patients taking metformin to determine the effects of modest elevations of serum creatinine on plasma lactic acid levels, compared with normal levels.

Materials and methods
Patients on metformin with serum creatinine above the upper limit of the reference range were identified from a computerised hospital register of diabetic patients. Those with a recent severe illness, cardiac failure, abnormal liver function tests and symptomatic peripheral vascular disease were excluded on the basis that any of these conditions could cause a rise in plasma lactic acid levels. Age-matched patients with normal serum creatinine <120 μmol/l (n=24) were then identified and invited to participate in the study. All subjects had been taking metformin for a minimum period of six months. Reference plasma lactic acid levels were determined using healthy non-diabetic controls, mean 1.742 μmol/l (SD 0.819).

Patient characteristics were recorded (table). A physical examination with particular regard to exclusion criteria was performed. Venous blood samples were withdrawn at 09.00h following an overnight fast for urea while samples for estimation of electrolytes, serum creatinine, liver function tests, HbA1c, serum B12 and plasma lactate were withdrawn prior to the patient’s first dose of metformin.

Plasma lactate was measured using a Boehringer kit. The principle of this method is the oxidation of L-lactate to pyruvate by lactate dehydrogenase, NADH is formed from NAD and acts as the indicator as it is proportional to the amount of lactate originally present. Normal plasma lactate levels (mean 1.742
Table  Characteristics and results of diabetic subjects with normal and raised creatinine

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>Creatinine &lt;120 µmol/l</th>
<th>Creatinine &gt;120 µmol/l</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M:F)</td>
<td>19:15</td>
<td>11:14</td>
<td>5:12</td>
<td>NS</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>64.5</td>
<td>60.7</td>
<td>66.5</td>
<td>NS</td>
</tr>
<tr>
<td>Serum creatinine (µmol/l)</td>
<td>94.2 (10.3)</td>
<td>101.7 (11.6)</td>
<td>132.2 (9.5)</td>
<td>&lt;0.00001</td>
</tr>
<tr>
<td>Plasma lactate (mmol/l)</td>
<td>1.7 (0.8)</td>
<td>2.64 (1.4)</td>
<td>2.3 (0.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Metformin dose (mg)</td>
<td>1846 (616)</td>
<td>31.0 (6.2)</td>
<td>1717 (733)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg.m⁻²)</td>
<td>5.5 (1.7)</td>
<td>6.2 (1.9)</td>
<td>6.2 (1.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>6.5 (5.3)</td>
<td>10.6 (8.2)</td>
<td>10.6 (8.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Metformin use (years)</td>
<td>3.0 (2.9)</td>
<td>6.3 (5.4)</td>
<td>6.3 (5.4)</td>
<td>&lt;0.02</td>
</tr>
</tbody>
</table>

Results expressed as means (standard deviation). NS=non-significant. *Comparing subjects with creatinine <120 with creatinine >120

Learning points

- Metformin lowers blood glucose levels in diabetic patients
- Metformin does not cause hypoglycaemia
- Lactic acidosis is a rare adverse event
- Metformin increases lactic acid levels

The effectiveness of metformin is mediated by increased peripheral glucose uptake and a reduction in hepatic glucose production by inhibition of hepatic gluconeogenesis. A consequence of these actions is to increase blood lactate levels in all patients on metformin. Our results indicate that a modest elevation of serum creatinine is not associated with increased plasma lactate levels. The reported cases of metformin-associated lactic acidosis have occurred mainly in patients with severe renal impairment, in whom reduced clearance of metformin has resulted in accumulation leading to hyperlactataemia. Metformin is normally rapidly eliminated, with a plasma half-life of 1.7–4.5 h. This short elimination time suggests that accumulation of metformin may not occur with small elevations in serum creatinine and indeed, once daily dosing would guard against drug accumulation.

Monitoring of metformin-associated acidosis in different countries has shown that this remains an uncommon adverse effect over a 10-year period in the UK (1976–86) with only 0.027 cases per 1000 patient years (fatalities 0.017 per 1000 patient years). In Sweden, there were 0.024 per 1000 patient years from 1987–91 and it was reported that most of these cases were associated with cardiovascular or renal disease.

If metformin were to be strictly prohibited in patients with renal impairment, the alternative therapies are alpha-glucosidase inhibitors, sulphonylureas or insulin, all of which also have adverse effects. There have been fatalities related to insulin-induced hypoglycaemia and there is increasing evidence that recurring hypoglycaemia causes cumulative brain dysfunction. Sulphonylurea drugs can also cause fatal hypoglycaemia and have been associated with haemopoietic disorders, also with fatal outcome.

Many patients with type 2 diabetes are obese. Alternative therapeutic agents such as sulphonylureas or insulin tend to aggravate obesity whereas metformin does not. Metformin is a valuable drug in the management of type 2 diabetes and its use in the context of mild renal impairment should be further evaluated.

17 Noll F. Methods of enzymatic analysis. 2nd edn. HU Bergmeyer, p1475.

Medical Anniversary

JAMES YOUNG SIMPSON, 7 JUNE 1811

(Sir) James Young Simpson (1811–70) was born in Bathgate, Scotland, the seventh son of a baker. He was educated in Edinburgh, where he qualified in medicine (1830), became an MD (1832), and was appointed professor of obstetrics (1839). He introduced chloroform for the management of labour (1847), and this was used by Queen Victoria (1853).

— DG James
Metformin treatment in NIDDM patients with mild renal impairment.

V. Connolly and C. M. Kesson

doi: 10.1136/pgmj.72.848.352

Updated information and services can be found at:
http://pmj.bmj.com/content/72/848/352

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/